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Current knowledge & research questions  
Current knowledge 
 Maternal opioid usage is increasing [1] 
 Better short-term outcomes in infants who 
received methadone compared to 
morphine [2] 
 Current recommendations are often quite 
complex and require weaning period 
[1]  JAMA 2012;307 (18):1934-40 
[2]  JAMA 2018;172 (8): 741-48 
Research questions 
 Characterize pharmacokinetics (PK) of 
methadone in preterm neonates? 
 Influence of age & weight on PK profile of 
methadone in preterm neonates? 
 Assess target exposure levels? 
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LOS = Length of stay 
How to answer these questions? 
1. Characterize 
pharmacokinetic data 
2. Develop population 
PK model 
3. Evaluate methadone 
dosing recommendations 
- Single center open-label PK study in 
preterm neonates 
- 0.1 mg/kg po methadone 
- Estimate PK parameters (CL, Vd) 
- Assess influence of demographics 
(weight / postnatal age / …) 
- Investigate exposure levels (AUC) 
- Examine feasibiliy of current and 
simplified dosing recommendations  
© UKBB Pediatric Pharmacology 
CL = Clearance 
Vd = Volume of distribution 
AUC = Area under the curve 
Results - Pharmacokinetic data  
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Study participants (n=31) 
Median (range) 
Bodyweight (kg) 1.6 (0.93 – 2.7) 
Gestational age (weeks) 32 (26 – 36) 
Postnatal age (days) 3 (0 – 15)  
Post menstrual age (weeks) 32 (26 – 37) 
Maternal age (years) 25 (17 – 34) 
Sex   
   Female 10 [32%] 
   Male 20 [65%] 
   Unknown 1 [3%] 
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121 methadone plasma concentrations 
Results - PK parameters 
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1. One-compartment model, first-order absorption and elimination kinetics  
2. CL increases with advancing gestational age  
3. CL values are higher for R-methadone (0.244 L/h) as compared to S-
methadone (0.167 L/h) 
CL = Clearance 









Day 1 0.1 0.1 q6 x 4 
Day 2 0.075 0.1 q12 x 2 
Day 3 0.05 0.05 q12 x 2 
Day 4 0.04 0.01 q12 x 2 
Day 5 0.03 - q12 x 2 
Day 6 0.02 - q12 x 2 
Day 7 0.01 - q12 x 2 
Day 8 0.01 - q24 x 1 
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Target exposure ? 
985 mcg∙h/L [1] 
[1] JPEDS 2015, 167: 1214-20 
Results - Dosing strategies 
Target methadone exposure 
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Current practice 5 59 89 97 99 100 100 100 100 70 37 17 
New schedule 5 62 91 97 99 100 100 100 100 56 27 11 
Conclusion 
9 
 Clearance of methadone increases with advancing gestational age 
 
 Pharmacokinetic differences between the two enantiomers were 
observed (higher CL for R-methadone) 
 
 Complex dosing schemes could be replaced by a simplified and 
shortened dosing strategy (validation study required!) 
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Discussion 
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 Unexplained variability  
 Polymorphisms of CYP2B6 enzyme 
 Breastfeeding effect 
 Neonatal exposure through breastmilk is minimal  
 Decreased severity of NAS has been observed (effect due to 
methadone or calming and nursing effect of breastfeeding) 
 Target exposure applied from earlier research in term neonates 
 
 Future steps 
 Validation study of simplified methadone dosing strategies 
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Goodness of fit  
Final PK model 
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Parameter estimates  




Estimate % RSE 
Bootstrap analysis 
Estimate % RSE 
Bootstrap analysis 
Median 95% CI Median 95% CI 
Population parameters  
Ka (h
-1) 1.73 0.57 1.69 1.15-2.90 2.65 0.08 1.20 0.79-1.89 
Vd/F (L) 26.9 1.89 27.5 21.9-33.2 18 0.13 16.73 13.77-19.95 
CL/F (L/h) 0.24 0.04 0.25 0.18-0.33 0.17 5.24 0.18 0.12-0.23 
GA effect 5.29 1.75 5.86 3.14-9.07 5.16 0.46 4.99 1.94-8.74 
Inter-individual variability - % CV* 
Ka (h
-1) 0.05 - - - 0.05 - - - 
Vd/F (L) 0.39 69 0.36 0.21-0.56 0.30 59 0.33 0.16-0.54 
CL/F (L/h) 0.20 47 0.19 0.009-0.4 0.19 46 0.18 0.02-0.42 
Residual variability  
Proportional error 0.106 - 0.101 0.07-0.13 0.115 - 0.102 0.06-0.13 
